Skip to main content
SpringerLink
Log in

Inflammatory Biomarkers for Cancer

  • Chapter
  • First Online:
Biomarkers of the Tumor Microenvironment

  • 1237 Accesses

Abstract

Cancer is associated with various degrees of inflammation both locally and systemically, resulting from an immunological response towards malignant lesions. Here, we critically evaluate several inflammatory parameters as biomarkers and prognostic tools for cancer. Colorectal cancer (CRC) represents a paradigm of the causative relationship between chronic inflammatory disease and cancer development. However, close examination reveals that for CRC, risk in patients with inflammatory bowel disease (IBD) has been largely overestimated. In fact, IBD patients only have a slightly increased risk of developing CRC (standardized incidence ratio ~ 1.7), which only weakly supports the link between chronic inflammation and cancer. However, long-term immunosuppressive treatment of IBD patients is associated with an increased risk for overall cancer, particularly haematologic and skin cancers. In contrast, there is a strong association between infection with the bacterium Helicobacter pylori, gastritis, and gastric cancer. Therefore, H. pylori seropositivity or the associated gastritis may be used as predictive biomarkers for cancer, although the rate of false positives is high. We have also reviewed several cytokines of the interleukin-1 family and cytokines that converge on STAT3 signalling because they are very well suited to illustrate the multitude of cytokine actions that makes interpretation of one single cytokine as a biomarker of cancer very complex. In addition, we describe in more detail the biology of IL-33, the most recently identified member of the IL-1 family, because it has not yet been subject to review in the context of cancer immunology.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Haabeth OA, Bogen B, Corthay A. A model for cancer-suppressive inflammation. Oncoimmunology. 2012;1(7):1146–55.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Danese S, Mantovani A. Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene. 2010;29(23):3313–23.

    Article  CAS  PubMed  Google Scholar 

  3. Jess T, Frisch M, Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol Hepatol. 2013;11(1):43–8.

    Article  PubMed  Google Scholar 

  4. Farraye FA, Odze RD, Eaden J, Itzkowitz SH, McCabe RP, Dassopoulos T, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138(2):738–45.

    Article  PubMed  Google Scholar 

  5. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology. 2012;143(2):382–9.

    Article  PubMed  Google Scholar 

  7. Beaugerie L, Svrcek M, Seksik P, Bouvier AM, Simon T, Allez M, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 2013;145(1):166–75.e8.

    Article  PubMed  Google Scholar 

  8. Jess T, Gamborg M, Matzen P, Munkholm P, Sorensen TI. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol. 2005;100(12):2724–9.

    Article  PubMed  Google Scholar 

  9. Soderlund S, Brandt L, Lapidus A, Karlen P, Brostrom O, Lofberg R, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology. 2009;136(5):1561–7. quiz 818–9

    Article  PubMed  Google Scholar 

  10. Jess T, Simonsen J, Jorgensen KT, Pedersen BV, Nielsen NM, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012;143(2):375–81.e1. quiz e13–4

    Article  PubMed  Google Scholar 

  11. Baars JE, Looman CW, Steyerberg EW, Beukers R, Tan AC, Weusten BL, et al. The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study. Am J Gastroenterol. 2011;106(2):319–28.

    Article  PubMed  Google Scholar 

  12. Brown LM. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev. 2000;22(2):283–97.

    Article  CAS  PubMed  Google Scholar 

  13. Linz B, Balloux F, Moodley Y, Manica A, Liu H, Roumagnac P, et al. An African origin for the intimate association between humans and Helicobacter pylori. Nature. 2007;445(7130):915–8.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Maixner F, Krause-Kyora B, Turaev D, Herbig A, Hoopmann MR, Hallows JL, et al. The 5300-year-old Helicobacter pylori genome of the Iceman. Science. 2016;351(6269):162–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Warren JR. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;1(8336):1273–5.

    CAS  PubMed  Google Scholar 

  16. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1(8390):1311–5.

    Article  CAS  PubMed  Google Scholar 

  17. Fiocca R, Villani L, Turpini F, Turpini R, Solcia E. High incidence of Campylobacter-like organisms in endoscopic biopsies from patients with gastritis, with or without peptic ulcer. Digestion. 1987;38(4):234–44.

    Article  CAS  PubMed  Google Scholar 

  18. Niemela S, Karttunen T, Lehtola J. Campylobacter-like organisms in patients with gastric ulcer. Scand J Gastroenterol. 1987;22(4):487–90.

    Article  CAS  PubMed  Google Scholar 

  19. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991;325(16):1132–6.

    Article  CAS  PubMed  Google Scholar 

  20. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325(16):1127–31.

    Article  CAS  PubMed  Google Scholar 

  21. Enomoto H, Watanabe H, Nishikura K, Umezawa H, Asakura H. Topographic distribution of Helicobacter pylori in the resected stomach. Eur J Gastroenterol Hepatol. 1998;10(6):473–8.

    Article  CAS  PubMed  Google Scholar 

  22. Hansen S, Melby KK, Aase S, Jellum E, Vollset SE. Helicobacter pylori infection and risk of cardia cancer and non-cardia gastric cancer. A nested case-control study. Scand J Gastroenterol. 1999;34(4):353–60.

    Article  CAS  PubMed  Google Scholar 

  23. Sasazuki S, Inoue M, Iwasaki M, Otani T, Yamamoto S, Ikeda S, et al. Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case-control study. Cancer Epidemiol Biomark Prev. 2006 Jul;15(7):1341–7.

    Article  CAS  Google Scholar 

  24. Infection with Helicobacter Pylori. World health organization, international agency for research on cancer. IARC Monogr Eval Carcinog Risks Hum. 1994;61:177–240.

    Google Scholar 

  25. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784–9.

    Article  CAS  PubMed  Google Scholar 

  26. Watabe H, Mitsushima T, Yamaji Y, Okamoto M, Wada R, Kokubo T, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut. 2005;54(6):764–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Kokkola A, Kosunen TU, Puolakkainen P, Sipponen P, Harkonen M, Laxen F, et al. Spontaneous disappearance of Helicobacter pylori antibodies in patients with advanced atrophic corpus gastritis. APMIS. 2003;111(6):619–24.

    Article  PubMed  Google Scholar 

  28. Dinarello CA. Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev. 2010;29(2):317–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev. 2008;226:10–8.

    Article  PubMed  Google Scholar 

  30. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317(5834):121–4.

    Article  CAS  PubMed  Google Scholar 

  31. Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A. 2008;105(2):652–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science. 2007;317(5834):124–7.

    Article  CAS  PubMed  Google Scholar 

  33. Uronis JM, Muhlbauer M, Herfarth HH, Rubinas TC, Jones GS, Jobin C. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One. 2009;4(6):e6026.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Salcedo R, Worschech A, Cardone M, Jones Y, Gyulai Z, Dai RM, et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med. 2010;207(8):1625–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Mager LF, Riether C, Schurch CM, Banz Y, Wasmer MH, Stuber R, et al. IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms. J Clin Invest. 2015;125(7):2579–91.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Haabeth OA, Lorvik KB, Hammarstrom C, Donaldson IM, Haraldsen G, Bogen B, et al. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun. 2011;2:240.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Corthay A. Does the immune system naturally protect against cancer? Front Immunol. 2014;5:197.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015 Jul;21(7):677–87.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Dupaul-Chicoine J, Yeretssian G, Doiron K, Bergstrom KS, McIntire CR, LeBlanc PM, et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity. 2010;32(3):367–78.

    Article  CAS  PubMed  Google Scholar 

  40. Allen IC, TeKippe EM, Woodford RM, Uronis JM, Holl EK, Rogers AB, et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med. 2010;207(5):1045–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Zaki MH, Vogel P, Body-Malapel M, Lamkanfi M, Kanneganti TD. IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J Immunol. 2010;185(8):4912–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Lee JK, Kim SH, Lewis EC, Azam T, Reznikov LL, Dinarello CA. Differences in signaling pathways by IL-1beta and IL-18. Proc Natl Acad Sci U S A. 2004;101(23):8815–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Krelin Y, Voronov E, Dotan S, Elkabets M, Reich E, Fogel M, et al. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res. 2007;67(3):1062–71.

    Article  CAS  PubMed  Google Scholar 

  44. Hitzler I, Sayi A, Kohler E, Engler DB, Koch KN, Hardt WD, et al. Caspase-1 has both proinflammatory and regulatory properties in Helicobacter infections, which are differentially mediated by its substrates IL-1beta and IL-18. J Immunol. 2012;188(8):3594–602.

    Article  CAS  PubMed  Google Scholar 

  45. Haabeth OA, Lorvik KB, Yagita H, Bogen B, Corthay A. Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells. OncoImmunology. 2016;5(1):e1039763.

    Article  PubMed  Google Scholar 

  46. Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE, et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc. 2009;84(2):114–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, et al. MABp1, a first-in-class true human antibody targeting interleukin-1alpha in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014;15(6):656–66.

    Article  CAS  PubMed  Google Scholar 

  48. Fabbi M, Carbotti G, Ferrini S. Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP. J Leukoc Biol. 2015;97(4):665–75.

    Article  CAS  PubMed  Google Scholar 

  49. Oertli M, Sundquist M, Hitzler I, Engler DB, Arnold IC, Reuter S, et al. DC-derived IL-18 drives Treg differentiation, murine Helicobacter pylori-specific immune tolerance, and asthma protection. J Clin Invest. 2012;122(3):1082–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Nishio S, Yamada N, Ohyama H, Yamanegi K, Nakasho K, Hata M, et al. Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alpha-galactosylceramide and interleukin-18. Cancer Sci. 2008;99(1):113–20.

    CAS  PubMed  Google Scholar 

  51. Osaki T, Peron JM, Cai Q, Okamura H, Robbins PD, Kurimoto M, et al. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects. J Immunol. 1998;160(4):1742–9.

    CAS  PubMed  Google Scholar 

  52. Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, et al. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity. 1998;9(1):25–34.

    Article  CAS  PubMed  Google Scholar 

  53. Wong JL, Mailliard RB, Moschos SJ, Edington H, Lotze MT, Kirkwood JM, et al. Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells. J Immunother. 2011;34(3):270–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Orengo AM, Fabbi M, Miglietta L, Andreani C, Bruzzone M, Puppo A, et al. Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor. Int J Cancer. 2011;129(5):1116–25.

    Article  CAS  PubMed  Google Scholar 

  55. Fujita K, Ewing CM, Isaacs WB, Pavlovich CP. Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. Int J Cancer. 2011;129(2):424–32.

    Article  CAS  PubMed  Google Scholar 

  56. Carbotti G, Barisione G, Orengo AM, Brizzolara A, Airoldi I, Bagnoli M, et al. The IL-18 antagonist IL-18-binding protein is produced in the human ovarian cancer microenvironment. Clin Cancer Res. 2013;19(17):4611–20.

    Article  CAS  PubMed  Google Scholar 

  57. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479–90.

    Article  CAS  PubMed  Google Scholar 

  58. Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett. 1989;258(2):301–4.

    Article  CAS  PubMed  Google Scholar 

  59. Onda H, Kasuya H, Takakura K, Hori T, Imaizumi T, Takeuchi T, et al. Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 1999;19(11):1279–88.

    Article  CAS  PubMed  Google Scholar 

  60. Kuchler AM, Pollheimer J, Balogh J, Sponheim J, Manley L, Sorensen DR, et al. Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol. 2008;173(4):1229–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’? PLoS One. 2008;3(10):e3331.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Sundnes O, Pietka W, Loos T, Sponheim J, Rankin AL, Pflanz S, et al. Epidermal expression and regulation of interleukin-33 during homeostasis and inflammation: strong species differences. J Invest Dermatol. 2015;135(7):1771–80.

    Article  CAS  PubMed  Google Scholar 

  63. Pollheimer J, Bodin J, Sundnes O, Edelmann RJ, Skanland SS, Sponheim J, et al. Interleukin-33 drives a proinflammatory endothelial activation that selectively targets nonquiescent cells. Arterioscler Thromb Vasc Biol. 2013;33(2):e47–55.

    Article  CAS  PubMed  Google Scholar 

  64. Hu LA, Fu Y, Zhang DN, Zhang J. Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer. Asian Pac J Cancer Prev. 2013;14(4):2563–6.

    Article  PubMed  Google Scholar 

  65. Liu J, Shen JX, JL H, Huang WH, Zhang GJ. Significance of interleukin-33 and its related cytokines in patients with breast cancers. Front Immunol. 2014;5:141.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Yu XX, Hu Z, Shen X, Dong LY, Zhou WZ, Hu WH. IL-33 promotes gastric cancer cell invasion and migration via ST2-ERK1/2 pathway. Dig Dis Sci. 2015;60(5):1265–72.

    Article  CAS  PubMed  Google Scholar 

  67. Calon A, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, Cespedes MV, et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell. 2012;22(5):571–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Bergis D, Kassis V, Ranglack A, Koeberle V, Piiper A, Kronenberger B, et al. High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma. Transl Oncol. 2013;6(3):311–8.

    Article  PubMed  PubMed Central  Google Scholar 

  69. DP L, Zhou XY, Yao LT, Liu CG, Ma W, Jin F, et al. Serum soluble ST2 is associated with ER-positive breast cancer. BMC Cancer. 2014;14:198.

    Article  Google Scholar 

  70. Ishikawa K, Yagi-Nakanishi S, Nakanishi Y, Kondo S, Tsuji A, Endo K, et al. Expression of interleukin-33 is correlated with poor prognosis of patients with squamous cell carcinoma of the tongue. Auris Nasus Larynx. 2014;41(6):552–7.

    Article  PubMed  Google Scholar 

  71. Brunner SM, Rubner C, Kesselring R, Martin M, Griesshammer E, Ruemmele P, et al. Tumor-infiltrating, interleukin-33-producing effector-memory CD8(+) T cells in resected hepatocellular carcinoma prolong patient survival. Hepatology. 2015;61(6):1957–67.

    Article  CAS  PubMed  Google Scholar 

  72. Chen SF, Nieh S, Jao SW, MZ W, Liu CL, Chang YC, et al. The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol. 2013;231(2):180–9.

    Article  CAS  PubMed  Google Scholar 

  73. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell. 1999;98(3):295–303.

    Article  CAS  PubMed  Google Scholar 

  74. Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol. 2014;26(1):54–74.

    Article  CAS  PubMed  Google Scholar 

  75. Belluco C, Nitti D, Frantz M, Toppan P, Basso D, Plebani M, et al. Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol. 2000;7(2):133–8.

    Article  CAS  PubMed  Google Scholar 

  76. Putoczki TL, Thiem S, Loving A, Busuttil RA, Wilson NJ, Ziegler PK, et al. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell. 2013;24(2):257–71.

    Article  CAS  PubMed  Google Scholar 

  77. Musolino C, Allegra A, Profita M, Alonci A, Saitta S, Russo S, et al. Reduced IL-33 plasma levels in multiple myeloma patients are associated with more advanced stage of disease. Br J Haematol. 2013;160(5):709–10.

    Article  CAS  PubMed  Google Scholar 

  78. Tseng-Rogenski SS, Hamaya Y, Choi DY, Carethers JM. Interleukin 6 alters localization of hMSH3, leading to DNA mismatch repair defects in colorectal cancer cells. Gastroenterology. 2015;148(3):579–89.

    Article  CAS  PubMed  Google Scholar 

  79. He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, et al. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A. 2003;100(24):14133–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Rebouissou S, Amessou M, Couchy G, Poussin K, Imbeaud S, Pilati C, et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature. 2009;457(7226):200–4.

    Article  CAS  PubMed  Google Scholar 

  81. Rutz S, Wang X, Ouyang W. The IL-20 subfamily of cytokines—from host defence to tissue homeostasis. Nat Rev Immunol. 2014 Dec;14(12):783–95.

    Article  CAS  PubMed  Google Scholar 

  82. McGee HM, Schmidt BA, Booth CJ, Yancopoulos GD, Valenzuela DM, Murphy AJ, et al. IL-22 promotes fibroblast-mediated wound repair in the skin. J Invest Dermatol. 2013;133(5):1321–9.

    Article  CAS  PubMed  Google Scholar 

  83. Liao C, ZB Y, Meng G, Wang L, Liu QY, Chen LT, et al. Association between Th17-related cytokines and risk of non-small cell lung cancer among patients with or without chronic obstructive pulmonary disease. Cancer. 2015;121(Suppl 17):3122–9.

    Article  CAS  PubMed  Google Scholar 

  84. Wu T, Cui L, Liang Z, Liu C, Liu Y, Li J. Elevated serum IL-22 levels correlate with chemoresistant condition of colorectal cancer. Clin Immunol. 2013;147(1):38–9.

    Article  CAS  PubMed  Google Scholar 

  85. Wu T, Wang Z, Liu Y, Mei Z, Wang G, Liang Z, et al. Interleukin 22 protects colorectal cancer cells from chemotherapy by activating the STAT3 pathway and inducing autocrine expression of interleukin 8. Clin Immunol. 2014;154(2):116–26.

    Article  CAS  PubMed  Google Scholar 

  86. Nardinocchi L, Sonego G, Passarelli F, Avitabile S, Scarponi C, Failla CM, et al. Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer. Eur J Immunol. 2015;45(3):922–31.

    Article  CAS  PubMed  Google Scholar 

  87. Kirchberger S, Royston DJ, Boulard O, Thornton E, Franchini F, Szabady RL, et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med. 2013;210(5):917–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Park O, Wang H, Weng H, Feigenbaum L, Li H, Yin S, et al. In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression. Hepatology. 2011;54(1):252–61.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Massague J. TGFbeta in cancer. Cell. 2008;134(2):215–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14(6):e218–28.

    Article  CAS  PubMed  Google Scholar 

  91. Principe DR, Doll JA, Bauer J, Jung B, Munshi HG, Bartholin L, et al. TGF-beta: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst. 2014;106(2):djt369.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Itatani Y, Kawada K, Fujishita T, Kakizaki F, Hirai H, Matsumoto T, et al. Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis. Gastroenterology. 2013;145(5):1064–75.e11.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the Research Council of Norway, Norway Grants 2009–2014 under project contract NFI/R/2014/051, the South-Eastern Norway Regional Health Authority, and the Norwegian Cancer Society.

Author information

Authors and Affiliations

  1. Department of Pathology, Oslo University Hospital, Oslo, Norway

    Alexandre Corthay & Guttorm Haraldsen

Authors
  1. Alexandre Corthay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guttorm Haraldsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guttorm Haraldsen .

Editor information

Editors and Affiliations

  1. Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway

    Lars A. Akslen

  2. Vascular Biology Program, Department of Surgery, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA

    Randolph S. Watnick

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Corthay, A., Haraldsen, G. (2017). Inflammatory Biomarkers for Cancer. In: Akslen, L., Watnick, R. (eds) Biomarkers of the Tumor Microenvironment. Springer, Cham. https://doi.org/10.1007/978-3-319-39147-2_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-39147-2_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-39145-8

  • Online ISBN: 978-3-319-39147-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation